中国淋巴瘤治疗指南(2021年版)

Clinical practice guideline for lympoma in China(2021 Edition)

淋巴瘤是中国常见的恶性肿瘤之一。2020年中国新发霍奇金淋巴瘤6829例,死亡2807例;新发非霍奇金淋巴瘤92834例,死亡54351例。淋巴瘤病理类型复杂,异质性强,治疗原则各有不同。近年来,随着人们对淋巴瘤本质认识的不断深入,淋巴瘤在诊断和治疗方面出现了很多新的研究结果,患者生存得到了改善。为了及时反映国内外淋巴瘤治疗领域的进展,进一步提高中国淋巴瘤的规范化诊断和治疗水平,中国抗癌协会淋巴瘤专业委员会、中国医师协会肿瘤医师分会和中国医疗保健国际交流促进会肿瘤内科分会组织专家编写了中国淋巴瘤治疗指南(2021年版)。

Lymphoma is one of the most common malignancies in China.In China,there were 6829 new Hodgkin lymphoma cases and 2807 deaths in 2020,with 92834 new non-Hodgkin lymphoma cases and 54351 deaths.Due to the complicated pathological subtypes and heterogeity,the treatment strategies for lymphoma vary largely.In recent years,with the deep understanding for the nature of lymphoma,much research progress has been achieved in the diagnosis and treatment,leading to a remarkable improvement in survival outcome of patients.In order to update the progress in the treatment of lymphoma worldwide timely,and further improve the level of standardized diagnosis and treatment of lymphoma in China,the China Anti-cancer Association Lymphoma Committee,Chinese Association for Clinical Oncologists,and Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare organized experts to formulate"Clinical practice guideline for lympoma in China(2021 Edition)".